The “Bladder Cancer – Pipeline Review, H2 2017” report has been added to Research and Markets’ offering.
Bladder Cancer – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Bladder Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Bladder Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bladder Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 10, 53, 52, 5, 63, 12 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 7, 2, 10 and 3 molecules, respectively.
Bladder Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
– Bladder Cancer – Overview
– Bladder Cancer – Therapeutics Development
– Bladder Cancer – Therapeutics Assessment
– Bladder Cancer – Companies Involved in Therapeutics Development
– Bladder Cancer – Drug Profiles
– Bladder Cancer – Dormant Projects
– Bladder Cancer – Discontinued Products
– Bladder Cancer – Product Development Milestones
For more information about this report visit https://www.researchandmarkets.com/research/hxlsmw/bladder_cancer?w=3